扶正防癌方治疗晚期非小细胞肺癌的疗效观察  

Clinical Observation of Fuzheng Anti-cancer Prescription (扶正防癌方) In The Treatment of Advanced Non-small Cell Lung Cancer

作　　者：刘声[1] 吴洁[2] 孙书贤[1] 关丽[1] LIU Sheng;WU Jie;SUN Shu-xian;GUAN Li(Beijing Hospital of Traditional Chinese Medicine,Capital Medical University,Beijing 100010,China;Guang＇anmen Hospital,Chinese Academy of Chinese Medicine Sciences,Beijing 100053,China)

机构地区：[1]首都医科大学附属北京中医医院,北京100010 [2]中国中医科学院广安门医院,北京100053

出　　处：《中医药导报》2018年第17期36-39,共4页Guiding Journal of Traditional Chinese Medicine and Pharmacy

基　　金：北京市卫生系统高层次卫生技术人才培养项目

摘　　要：目的:探讨具有补益脾肾作用的扶正防癌方治疗脾肾两虚型晚期非小细胞肺癌(SCLC)的疗效及对患者外周血调节性T细胞(Treg细胞)的影响。方法:将46例晚期NSCLC患者,随机分为治疗组和对照组,每组23例。比较两组外周血液中Treg细胞百分占比和细胞因子含量,比较两组实体瘤近期疗效,体质量及Karnofsky评分、生活质量QOL-C30评分、中医证候积分。结果:治疗组治疗后外周血Treg细胞百分比、细胞因子含量低于治疗前,差异均有统计学意义(P<0.05);对照组治疗前后比较,差异无统计学意义(P>0.05)。治疗后两组体质量及Karnofsky评分、中医证候积分、生活质量QOL-C30评分均升高,且治疗组高于对照组,差异均有统计学意义(P<0.05);两组实体瘤近期疗效比较,差异无统计学意义(P>0.05)。结论:扶正防癌方能调节Treg细胞及细胞因子,改善临床症状和生活质量,是晚期NSCLC患者可选择的有效的临床治疗方法之一。Objective： To investigate the therapeutic effect of Fuzheng Anti-cancer Prescription on advanced non-small cell lung cancer（SCLC） with deficiency of both spleen and kidney and its effect on regulatory Treg cells in peripheral blood of patients. Methods： A total of 46 patients with advanced NSCLC were randomly divided into the treatment group and the control group, 23 patients in each group. The percentage ratio and cytokine content of Treg cells in peripheral blood, the short-term curative effect of solid tumors, the physical quality and Karnofsky score, QOL-C30 score and TCM syndromes score were compared between the two groups.Results： The percentage of peripheral blood Treg cells and cytokine content were lower in the treatment group than before（P〈0.05）. There was no significant difference between before and after treatment in the control group（P〈0.05）. After treatment, both groups had higher physical quality, Karnofsky score, TCM score, and QOLC30 score, and the treatment group was higher than the control group. The difference was statistically significant（P〈0.05）. There was no significant difference in the short-term curative effect of solid tumors between two groups（P〈0.05）. Conclusion： Fuzheng Anti-cancer Prescription can regulate Treg cells and cytokines, improve clinical symptoms and quality of life, is one of the effective clinical treatment options for advanced NSCLC patients.

关 键 词：晚期非小细胞肺癌 补益脾肾法 扶正防癌方 临床观察 

分 类 号：R273[医药卫生—中西医结合]